Biomedical subjects

S Steciw

Publications and source records attributed to S Steciw.

3 recordsLinked to original sources

PubMed2005

Three-dimensional IMRT verification with a flat-panel EPID.

A three-dimensional (3D) intensity-modulated radiotherapy (IMRT) pretreatment verification procedure has been developed based on the measurement of two-dimensional (2D) primary fluence profiles using an amorphous silicon flat-panel electronic portal imaging device (EPID). As described in our previous work, fluence profiles are extracted from EPID images by deconvolution with kernels that represent signal spread in the EPID due to radiation and optical scattering. The deconvolution kernels are derived using Monte Carlo simulations of dose deposition in the EPID and empirical fitting methods, for both 6 and 15 MV photon energies. In our new 3D verification technique, 2D fluence modulation profiles for each IMRT field in a treatment are used as input to a treatment planning system (TPS), which then generates 3D doses. Verification is accomplished by comparing this new EPID-based 3D dose distribution to the planned dose distribution calculated by the TPS. Thermoluminescent dosimeter (TLD) point dose measurements for an IMRT treatment of an anthropomorphic phantom were in good agreement with the EPID-based 3D doses; in contrast, the planned dose under-predicts the TLD measurement in a high-gradient region by approximately 16%. Similarly, large discrepancies between EPID-based and TPS doses were also evident in dose profiles of small fields incident on a water phantom. These results suggest that our 3D EPID-based method is effective in quantifying relevant uncertainties in the dose calculations of our TPS for IMRT treatments. For three clinical head and neck cancer IMRT treatment plans, our TPS was found to underestimate the mean EPID-based doses in the critical structures of the spinal cord and the parotids by approximately 4 Gy (11%-14%). According to radiobiological modeling calculations that were performed, such underestimates can potentially lead to clinically significant underpredictions of normal tissue complication rates.

Algorithms↗

PubMed2004

Modeling scintillator-photodiodes as detectors for megavoltage CT.

The use of cadmium tungstate (CdWO4) and cesium iodide [CsI(Tl)] scintillation detectors is studied in megavoltage computed tomography (MVCT). A model describing the signal acquired from a scintillation detector has been developed which contains two steps: (1) the calculation of the energy deposited in the crystal due to MeV photons using the EGSnrc Monte Carlo code; and (2) the transport of the optical photons generated in the crystal voxels to photodiodes using the optical Monte Carlo code DETECT2000. The measured detector signals in single CdWO4 and CsI(Tl) scintillation crystals of base 0.275 x 0.8 cm2 and heights 0.4, 1, 1.2, 1.6 and 2 cm were, generally, in good agreement with the signals calculated with the model. A prototype detector array which contains 8 CdWO4 crystals, each 0.275 x 0.8 x 1 cm3, in contact with a 16-element array of photodiodes was built. The measured attenuation of a Cobalt-60 beam as a function of solid water thickness behaves linearly. The frequency dependent modulation transfer function [MTF(f)], noise power spectrum [NPS(f)], and detective quantum efficiency [DQE(f)] were measured for 1.25 MeV photons (in a Cobalt-60 beam). For 6 MV photons, only the MTF(f) was measured from a linear accelerator, where large pulse-to-pulse fluctuations in the output of the linear accelerator did not allow the measurement of the NPS(f). A two-step Monte Carlo simulation was used to model the detector's MTF(f), NPS(f) and DQE(f). The DQE(0) of the detector array was found to be 26% and 19% for 1.25 MeV and 6 MV photons, respectively. For 1.25 MeV photons, the maximum discrepancies between the measured and modeled MTF(f), relative NPS(f) and the DQE(f) were found to be 1.5%, 1.2%, and 1.9%, respectively. For the 6 MV beam, the maximum discrepancy between the modeled and the measured MTF(f) was found to be 2.5%. The modeling is sufficiently accurate for designing appropriate detectors for MVCT.

Computer-Aided Design↗

PubMed2003

Dosimetric IMRT verification with a flat-panel EPID.

A convolution-based calibration procedure has been developed to use an amorphous silicon flat-panel electronic portal imaging device (EPID) for accurate dosimetric verification of intensity-modulated radiotherapy (IMRT) treatments. Raw EPID images were deconvolved to accurate, high-resolution 2-D distributions of primary fluence using a scatter kernel composed of two elements: a Monte Carlo generated kernel describing dose deposition in the EPID phosphor, and an empirically derived kernel describing optical photon spreading. Relative fluence profiles measured with the EPID are in very good agreement with those measured with a diamond detector, and exhibit excellent spatial resolution required for IMRT verification. For dosimetric verification, the EPID-measured primary fluences are convolved with a Monte Carlo kernel describing dose deposition in a solid water phantom, and cross-calibrated with ion chamber measurements. Dose distributions measured using the EPID agree to within 2.1% with those measured with film for open fields of 2 x 2 cm2 and 10 x 10 cm2. Predictions of the EPID phantom scattering factors (SPE) based on our scatter kernels are within 1% of the SPE measured for open field sizes of up to 16 x 16 cm2. Pretreatment verifications of step-and-shoot IMRT treatments using the EPID are in good agreement with those performed with film, with a mean percent difference of 0.2 +/- 1.0% for three IMRT treatments (24 fields).

Canada↗